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Did Dumbo suffer a heart attack?
independent association between earlobe
crease and cardiovascular disease
Marta Aligisakis1,2*, Pedro Marques-Vidal2, Idris Guessous3,4 and Peter Vollenweider2
Abstract
Background: Earlobe crease (ELC) has been associated with cardiovascular diseases (CVD) or risk factors (CVRF) and
could be a marker predisposing to CVD. However, most studies studied only a small number of CVRF and no complete
assessment of the associations between ELC and CVRF has been performed in a single study.
Methods: Population-based study (n= 4635, 46.7 % men) conducted between 2009 and 2012 in Lausanne, Switzerland.
Results: Eight hundred six participants (17.4 %) had an ELC. Presence of ELC was associated with male gender and older
age. After adjusting for age and gender (and medication whenever necessary), presence of ELC was significantly (p < 0.05)
associated with higher levels of body mass index (BMI) [adjusted mean ± standard error: 27.0 ± 0.2 vs. 26.02 ± 0.07 kg/m2],
triglycerides [1.40 ± 0.03 vs. 1.36 ± 0.01 mmol/L] and insulin [8.8 ± 0.2 vs. 8.3 ± 0.1 μIU/mL]; lower levels of HDL cholesterol
[1.61 ± 0.02 vs. 1.64 ± 0.01 mmol/L]; higher frequency of abdominal obesity [odds ratio and (95 % confidence
interval) 1.20 (1.02; 1.42)]; hypertension [1.41 (1.18; 1.67)]; diabetes [1.43 (1.15; 1.79)]; high HOMA-IR [1.19 (1.00;
1.42)]; metabolic syndrome [1.28 (1.08; 1.51)] and history of CVD [1.55 (1.21; 1.98)]. No associations were found
between ELC and estimated cardiovascular risk, inflammatory or liver markers. After further adjustment on BMI,
only the associations between ELC and hypertension [1.30 (1.08; 1.56)] and history of CVD [1.47 (1.14; 1.89)]
remained significant. For history of CVD, further adjustment on diabetes, hypertension, total cholesterol and
smoking led to similar results [1.36 (1.05; 1.77)].
Conclusion: In this community-based sample ELC was significantly and independently associated with hypertension
and history of CVD.
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Background
Cardiovascular disease (CVD) is the most common cause
of morbidity and mortality in industrialized countries. Most
cardiovascular risk factors (CVRF) involve specific investi-
gations (i.e. total, LDL or HDL cholesterol; glucose) and
might not be suitable in low or middle-income countries,
where access to health resources is scarce. Thus, the identi-
fication of simple clinical signs associated with an increased
risk of CVD has drawn some attention. One of these signs
is the earlobe crease (ELC), defined as “a deep crease in the
lobule portion of the auricle” by S.T. Frank in 1973 [1].
Similarly to the heart, earlobes have an end-artery-type of
microcirculation without collaterals and become quickly
anoxic if end-arteries are occluded [2]. Therefore, CVRF
associated with altered microcirculation might impact ELC
due to a local micro vascular insufficiency associated with
atherosclerosis [2–7].
In cross-sectional studies, ELC was associated with
hypertension [8–10], obesity [2, 8], metabolic syndrome
(MS) [11], atherosclerosis [8, 12], and coronary artery
disease (CAD) [6, 9, 10, 13–15]. Various autopsy or
biopsy studies also found an association between ELC
and systemic atherosclerosis [6, 16–19] or death from
CVD [20]. Further, ELC was considered an independent
and early sign predisposing to CVD in several prospect-
ive studies [6, 10, 21–24]. However, some studies failed
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to find any association between ELC and CAD [25–27]
or CVRF [13, 14, 21–23, 28] and two studies suggested
that the association of CVD with ELC was entirely
accounted for by increasing age [25, 29]. Some of these
discrepancies might be related to the fact that most
studies focused on a limited number of CVRF and none
evaluated in detail the association between ELC and a
large panel of established or putative CVRF such as
inflammatory markers and adipokines.
Thus, the aim of this study was to assess the associations
of ECL with a large panel of CVRF and also with CVD in a
population-based sample of adults.
Methods
Recruitment
Details of the CoLaus study have been reported previously
[30–32]. Briefly, CoLaus is a prospective, population-based
study conducted in the city of Lausanne, Switzerland. The
main aim is to better understand the prevalence of
biological and genetic determinants of CVRF and
CVD. The baseline assessment was conducted be-
tween 2003 and 2006 and included 6733 participants
aged 35 to 75 years. The first follow-up was conducted
between April 2009 and September 2012 and included
5064 participants (75.2 % of the initial sample). Non-
participation was due to death in 164 (2.4 %) partici-
pants, to migration to other countries in 222 (3.3 %),
to refusal in 1100 (16.3 %) and to non-traceability in
183 (2.7 %). The current results are based on the 5064
participants in the first follow-up.
The CoLaus Study was approved by the Institutional
Ethics Committee of the University of Lausanne (decision
19 February 2003, protocol number 16/03). All participants
provided written informed consent.
Personal history
Personal history of CAD, angina pectoris, myocardial
infarction (MI), stroke and coronary artery bypass graft
(CABG) was assessed by questionnaire. Family history
included MI and stroke in the mother and/or the father.
Smoking status was self-reported and defined as never,
former (irrespective of the time since quitting) and current.
Antihypertensive, lipid-lowering and antidiabetes medica-
tion was self-reported and defined as present or absent.
Total daily energy expenditure was assessed by a
validated questionnaire (PAFQ) where the participant
indicated the average daily duration of different types
of physical activity (i.e. household, at work, sports)
[33]. Energy expenditure was expressed in Kcalories
per day and sedentary status was defined as expending
less than 10 % of the daily energy in moderate- and
high-intensity activities (at least 4 times the basal
metabolic rate).
Clinical data
Earlobe crease, defined as a crease in the lobule portion
of the auricle, was systematically searched during the
clinical examination by trained field investigators and
coded as absent, unilateral or bilateral. A second coding
(ELC present/absent) was also used for analysis.
Body weight and height were measured with partici-
pants standing without shoes in light indoor clothes.
Body weight was measured in kilograms to the nearest
100 g using a Seca® scale (Hamburg, Germany). Height
was measured to the nearest 5 mm using a Seca® gauge
(Hamburg, Germany). Body mass index (BMI) was
defined as weight (kg)/height (m)2.
Waist circumference was measured with a non-
stretchable tape over the unclothed abdomen at the
narrowest point between the lowest rib and the iliac crest.
Two measures were made and the mean, expressed in cen-
timetres, was used for analyses. Abdominal obesity was de-
fined as a waist circumference >102 cm (men) and >88 cm
(women) according to the National Cholesterol Education
Program–Adult Treatment Panel III (NCEP-ATP III).
Blood pressure was measured thrice on the left arm,
with an appropriately sized cuff, after a rest of at least
10 min in the seated position using a Omron® HEM-907
automated oscillometric sphygmomanometer (OMRON,
Japan). The average of the last two measurements was
used for analyses. Hypertension was defined as a systolic
blood pressure (SBP) >140 mmHg or a diastolic blood
pressure (DBP) >90 mmHg or presence of antihyperten-
sive medication.
Biological data
Laboratory markers were measured in venous blood sam-
ples drawn after an overnight fast. For cytokine measure-
ments, serum was preferred to plasma because the absolute
cytokine level could be influenced by different anticoagu-
lants [34]. Most biological assays were performed by the
CHUV Clinical Laboratory on fresh blood samples within
2 h of blood collection, and additional aliquots were stored
at –80 °C. Most measurements were conducted in a Modu-
lar P apparatus (Roche Diagnostics, Switzerland).
Total cholesterol was assessed by CHOD-PAP; high-
density lipoprotein (HDL) cholesterol was assessed by
CHOD-PAP + PEG + cyclodextrin; triglycerides were
assessed by GPO-PAP; low-density lipoprotein (LDL)
cholesterol was calculated using the Friedewald for-
mula if triglycerides were <4.6 mmol/L.
Glucose was assessed by glucose dehydrogenase; insulin
was assessed by a solid-phase, two-site chemiluminescent
immunometric assay (Diagnostic Products Corporation,
Los Angeles, USA); Homeostatic model assessment insulin
resistance (HOMA-IR) was calculated as glucose
(mmol/L) x insulin (μIU/mL)/ 22.5. High HOMA-IR
was defined as >2.6. Diabetes was defined as a fasting
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plasma glucose >7.0 mmol/L or presence of antidia-
betes medication.
Inflammatory markers included high sensitivity-C-
reactive protein (hs-CRP), Interleukin 1β (IL-1β), inter-
leukin 6 (IL-6) and tumour necrosis factor-α (TNF-α).
Hs-CRP was assessed by immunoassay and latex HS
(Immulite 1000–High, Diagnostic Products Corporation,
LA, CA, USA) while the other markers were measured
using a multiplexed particle-based flow cytometric cyto-
kine assay (Millipore, Zug, Switzerland). Lower detection
limits for IL-1β, IL-6 and TNF-α were 0.2 ng/L. As many
participants had cytokine levels below detection limits
(28 % for IL-1β and 4.5 % for IL-6), inflammatory markers
were categorized into quartiles and undetectable values
were included in the first quartile. Log-transformed values
of available levels were also used in the analysis.
Leptin was measured by ELISA (American Laboratory
Products Company, Windham, USA). Adiponectin was
assessed by ELISA (R&D Systems, Inc, Minneapolis,
USA). Uric acid was assessed by uricase-PAP and creatin-
ine was assessed by the Jaffe kinetic compensated method.
Aspartate aminotransferase (ASAT), alanine aminotrans-
ferase (ALAT), γ-glutamyl transpeptidase (γ-GT) and alka-
line phosphatase were assessed by the optimized standard
method according to the International Federation of Clin-
ical Chemistry at 37 °C.
Other variables
Metabolic syndrome was defined according to the NCEP
ATP-III as at least three of the following criteria: 1)
waist circumference >102 cm (men) and >88 cm
(women), 2) triglycerides ≥1.7 mmol/L and/or HDL chol-
esterol <1.03 mmol/L (men) or <1.29 mmol/L (women) or
lipid lowering medication, 3) Blood pressure ≥130/85 mm
Hg or antihypertensive medication, 4) Fasting plasma
glucose ≥5.6 mmol/L or antidiabetes medication.
Cardiovascular risk was estimated using three differ-
ent equations: a calibrated SCORE [35], the original
Framingham 1998 equation, and a calibrated version of the
Framingham 1998 equation for the Swiss population [36].
Statistical analysis
Statistical analyses were performed using Stata version
13.1 for Windows (Stata Corp, College Station, Texas,
USA). Bivariate statistical analyses were performed by
Student’s t-test for quantitative variables and by chi-
square for categorical variables. Results were expressed
as mean ± standard deviation or as number of partici-
pants (percentage). Sensitivity, specificity, positive and
negative predictive values for presence versus absence of
ELC were computed and presented with their 95 % con-
fidence intervals. For quantitative variables, multivariable
analyses were performed by ANOVA and the results
were expressed as adjusted mean ± standard error. For
categorical variables (excluding smoking), multivariable
analyses were performed by logistic regression and
results were expressed as odds ratio (OR) and 95 %
confidence interval. For smoking, multivariable analyses
were performed using multivariate (polytomous) logistic
regression and the results were expressed as relative risk
ratio (95 % confidence interval). Two models were
applied: adjusted for 1) age and gender and 2) age,
gender, and BMI. Analyses were also adjusted for medi-
cation whenever appropriate. As cardiovascular risk
equations already include cardiovascular risk factors, no
adjustment was performed for CVRF. For sensitivity
analysis, a model similar to 2) but adjusting for waist
circumference instead of BMI was applied; similarly, for
history of CVD a further adjustment for hypertension,
diabetes, total cholesterol and smoking was performed.
Statistical significance was assessed for a two-sided test
p-value <0.05.
Results
Characteristics of participants
Of the 5064 participants of the first follow-up, 429
(8.5 %) were excluded because of missing data regarding
ELC. Excluded participants were older, had a higher SBP
and presented more often with hypertension and abdom-
inal obesity than included participants; the other main char-
acteristics and biological markers did not differ between the
two groups (Additional file 1: Table S1). The remaining
4635 participants (46.7 % men) had a mean age of 57.8 ±
10.5 years and a mean BMI of 26.2 ± 4.6 kg/m2. Eight
hundred and six (17.4 %) participants had an ELC, of
which 373 (46.3 %) unilateral.
Association between ELC and CVRF
On bivariate analysis, presence of ELC was significantly
associated with higher BMI, SBP, DBP, triglyceride,
glucose and insulin levels, and with lower HDL choles-
terol levels. Presence of ELC was also associated with a
higher likelihood of presenting with abdominal obesity,
hypertension, diabetes, insulin resistance or metabolic
syndrome. Conversely, no association was found between
ELC and smoking status, total and LDL cholesterol
(Table 1). Sensitivity, specificity, positive and negative pre-
dictive values for presence versus absence of ELC regard-
ing cardiovascular risk factors are presented in Additional
file 2: Table S2. For all risk factors sensitivity and positive
predictive values were low, whereas specificity and nega-
tive predictive values were relatively high, namely regard-
ing personal history of CVD (Additional file 2: Table S2).
After multivariable adjustment on age, gender and
medication (whenever necessary), the associations of ELC
with BMI, abdominal obesity, hypertension, glucose and
insulin levels, diabetes, HOMA-IR, and MS remained
(Table 2). Similarly, significant associations were found
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between the number of ELC and BMI, hypertension,
HDL cholesterol, insulin levels, HOMA-IR and dia-
betes (Additional file 3: Table S3 and Additional file 4:
Table S4). After further adjustment for BMI, only
hypertension remained associated with ELC, while no
association was found with the number of ELC. Similar
findings were obtained when the analysis was adjusted for
waist instead of BMI (Additional file 5: Table S5).
Association between ELC and history or risk of CVD
The prevalence of ELC was 16 % in participants without
any history of CVD and 33.3 % in those with anamnestic
CVD (p value < 0.001).
On bivariate analysis, the presence of an ELC was
associated with personal history of CVD (CAD; MI;
angina pectoris; stroke) or CABG, and with a higher
CVD risk (Table 3). Most associations with personal
history of CVD remained significant after multivari-
able adjustment, while the associations with CVD
risk became non-significant (Tables 4). Similar find-
ings were obtained when the analysis was adjusted
for waist instead of BMI (Additional file 6: Table S6)
or when the analysis was adjusted for other CVRF
(Additional file 7: Table S7). Conversely, no associ-
ation was found between ELC and family history of
CVD (not shown).
Table 1 Bivariate analysis of the association between earlobe crease and selected cardiovascular risk factors (CoLaus study,
Lausanne, 2009-2012)
Earlobe crease Absence (n = 3829) Presence (n = 806) P-value
Men (%) 1708 (44.6) 455 (56.5) <0.001
Age (years) 56.3 ± 10.3 63.2 ± 9.7 <0.001
BMI (kg/m2) 25.94 ± 4.53 27.38 ± 4.85 <0.001
BMI categories (%)
Normal 1749 (46.2) 255 (32.2)
Overweight 1448 (38.2) 349 (44.1) <0.001
Obese 592 (15.6) 187 (23.6)
Abdominal obesity (%) 1382 (36.3) 362 (45.2) <0.001
Smoking status (%)
Never 1619 (42.3) 300 (37.2)
Former 1358 (35.5) 347 (45.1) <0.001
Current 852 (22.2) 159 (19.7)
Blood pressure status
SBP (mm Hg) 125 ± 17 131 ± 19 <0.001
DBP (mm Hg) 78 ± 11 79 ± 11 <0.001
Hypertension (%) 1409 (36.9) 475 (58.9) <0.001
Lipids (mmol/L)
Total cholesterol 5.70 ± 1.03 5.68 ± 1.10 0.66
LDL cholesterol 3.45 ± 0.92 3.44 ± 0.98 0.88
HDL cholesterol 1.65 ± 0.47 1.59 ± 0.47 <0.001
Triglycerides 1.34 ± 0.90 1.47 ± 0.91 <0.001*
Glycaemic status
Glucose (mmol/L) 5.83 ± 1.06 6.20 ± 1.59 <0.001
Insulin (μIU/mL) 8.06 ± 6.82 9.75 ± 7.74 <0.001*
Diabetes (%) 343 (9.0) 147 (18.3) <0.001
HOMA-IR 2.21 ± 2.48 2.86 ± 2.65 <0.001
High HOMA-IR (%) 925 (24.2) 277 (34.4) <0.001
Metabolic syndrome (%) 1070 (28.2) 337 (42.1) <0.001
Results are expressed as number of participants (%) or as mean ± standard deviation. Statistical analysis by Student’s t-test or by chi-square
BMI body mass index; abdominal obesity and metabolic syndrome are defined by the NCEP ATP-III criteria; hypertension is defined as SBP > 140 or DBP > 90 mm
Hg and/or anti-hypertensive medication; LDL low-density lipoprotein; HDL high-density lipoprotein; HOMA-IR homeostatic model assessment of insulin resistance;
high HOMA-IR is defined as ≥2.6; diabetes is defined as fasting plasma glucose >7.0 mmol/L and/or anti-diabetes medication
*P-value calculated on log-transformed values
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Similar associations between ELC and personal history
of CVD were obtained after splitting the participants
with ELC on unilateral and bilateral ELC (Additional file
6: Table S6, Additional file 7: Table S7, Additional file 8:
Table S8, Additional file 9: Table S9).
Association between ELC and other markers
On bivariate analysis, presence of ELC was associated
with higher levels of leptin, uric acid, creatinine and
liver enzymes, while no association was found with
energy expenditure, sedentary status and adiponectin
levels (Additional file 10: Table S10). All associations
became non-significant after multivariable adjustment
(Additional file 11: Table S11) and similar findings
were obtained when adjusting for waist instead of
BMI (Additional file 12: Table S12).
On bivariate analysis, presence of ELC was posi-
tively associated with Hs-CRP and TNF-α, but not
with IL-1β or IL-6 (Additional file 13: Table S13).
After multivariable adjustment, a positive association
was found between ELC and IL-1β in quartiles, while
no association was found for the other inflammatory
markers (Additional file 14: Table S14). Similar results
were obtained when the analysis was performed on
log-transformed values, except that the association
between ELC and Il-1β was no longer significant
(Additional file 14: Table S14) or when the analysis
was adjusted for waist instead of BMI (Additional file
15: Table S15).
Table 2 Multivariable analysis of the association between earlobe crease and selected cardiovascular risk factors, CoLaus study,
Lausanne, 2009–2012
Adjusted for Age and gender Age, gender and body mass index
Earlobe crease Absence (n = 3829) Presence (n = 806) P-value Absence (n = 3829) Presence (n = 806) P-value
BMI (kg/m2) 26.0 ± 0.1 27.0 ± 0.2 <0.001 – – –
Abdominal obesity 1 (ref.) 1.20 (1.02; 1.42) <0.05 1 (ref.) 0.85 (0.66; 1.09) 0.19
Smoking status
Never – – – – – –
Former 1 (ref.) 1.17 (0.98; 1.40) 0.08 1 (ref.) 1.15 (0.96; 1.37) 0.14
Current 1 (ref.) 1.11 (0.89; 1.38) 0.34 1 (ref.) 1.16 (0.93; 1.45) 0.18
Blood pressure status
SBP (mm Hg)a 126 ± 1 126 ± 1 0.43 126 ± 1 126 ± 1 0.89
DBP (mm Hg)a 78 ± 1 79 ± 1 0.11 78 ± 1 78 ± 1 0.53
Hypertension 1 (ref.) 1.41 (1.18; 1.67) <0.001 1 (ref.) 1.30 (1.08; 1.56) <0.01
Lipids (mmol/L)b
Total cholesterol 5.70 ± 0.02 5.68 ± 0.04 0.69 5.70 ± 0.02 5.68 ± 0.04 0.53
LDL cholesterol 3.45 ± 0.01 3.45 ± 0.03 0.94 3.45 ± 0.01 3.43 ± 0.03 0.57
HDL cholesterol 1.64 ± 0.01 1.61 ± 0.02 0.05 1.64 ± 0.01 1.64 ± 0.01 0.93
Triglycerides 1.36 ± 0.01 1.40 ± 0.03 0.05* 1.36 ± 0.01 1.36 ± 0.03 0.65*
Glycaemic status
Glucose (mmol/L)c 5.88 ± 0.02 5.96 ± 0.04 0.06 5.88 ± 0.02 5.92 ± 0.04 0.36
Insulin (μIU/mL)c 8.3 ± 0.1 8.8 ± 0.2 0.01* 8.3 ± 0.1 8.4 ± 0.2 0.78*
HOMA-IRc 2.29 ± 0.04 2.47 ± 0.09 0.07 2.30 ± 0.04 2.33 ± 0.08 0.72
Diabetes 1 (ref.) 1.43 (1.15; 1.79) <0.01 1 (ref.) 1.25 (0.99; 1.59) 0.07
High HOMA-IR 1 (ref.) 1.19 (1.00; 1.42) <0.05 1 (ref.) 0.95 (0.78; 1.16) 0.62
Metabolic syndrome 1 (ref.) 1.28 (1.08; 1.51) <0.01 1 (ref.) 1.03 (0.84; 1.26) 0.79
For quantitative variables, multivariable analyses were performed by ANOVA and the results are expressed as adjusted mean ± standard error. For categorical variables
(excluding smoking), multivariable analyses were performed by logistic regression and results are expressed as odds ratio (95 % confidence interval). For smoking,
multivariable analyses were performed using multivariate (polytomous) logistic regression and the results are expressed as relative risk ratio (95 % confidence interval)
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; LDL low-density lipoprotein; HDL high-density lipoprotein; HOMA-IR homeostatic
model assessment of insulin resistance; high HOMA-IR is defined as a HOMA-IR ≥ 2.6; abdominal obesity and metabolic syndrome are defined by the NCEP ATP-III
criteria; hypertension is defined as SBP > 140 or DBP > 90 mm Hg or anti-hypertensive medication; diabetes is defined as fasting plasma glucose >7.0 mmol/L or
antidiabetes medication
*P-value calculated on log-transformed values
a,adjusting for antihypertensive medication
b,adjusting for hypolipidemic medication
c,adjusting for antidiabetes medication
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Discussion
To our knowledge, this is the most comprehensive study
on the associations between ELC and CVRF. Our results
show that ELC is significantly associated with hyperten-
sion and history of CVD independently of other risk
factors or potential confounders. Our results also sug-
gest that the associations with the other CVRF reported
in the literature could be due to confounding by age,
gender or BMI.
Association between ELC and CVRF
Prevalence of ELC was higher in men and increased with
age, a finding already reported [10, 11, 13, 26, 37]. A
possible explanation is the changes in skin collagen due
to aging, which would lead to the development of ELC
[2–7]. The higher prevalence of ELC in men could be
related to a higher prevalence of smoking, which would
accelerate the skin aging process. Still, no associations
between ELC and smoking status were found, a finding
in agreement with several other studies [2, 7, 8, 21], but
not with another [10]. Thus, the higher prevalence of
ELC in men remains an open question.
ELC was strongly and linearly associated with higher
BMI and abdominal obesity, a finding already reported by
two studies [2, 8] but not by another [10]. Interestingly,
most associations between ELC and CVRF or CVD were
no longer significant after adjusting for BMI, suggesting
that ELC might be a stronger marker of obesity than of
other CVRF. The fact that the associations between ELC
and hypertension, glucose level and history of CAD
remained significant after adjusting for BMI also suggests
that ELC could be used as a marker of these CVRF.
Table 3 Bivariate analysis of the association between earlobe crease and history or risk of cardiovascular disease, CoLaus study,
Lausanne, 2009–2012
Earlobe crease Absence (n = 3829) Presence (n = 806) P-value
History of
Any cardiovascular disease 244 (6.4) 122 (15.1) <0.001
Coronary artery disease 92 (2.4) 60 (7.5) <0.001
Angina pectoris 61 (1.6) 30 (3.7) <0.001
Myocardial infarction 60 (1.6) 34 (4.2) <0.001
Stroke 61 (1.6) 28 (3.5) <0.001
Coronary artery bypass graft 33 (0.9) 22 (2.7) <0.001
High cardiovascular disease risk
SCORE recalibrated 466 (12.2) 221 (27.5) <0.001
Framingham 1998 355 (9.3) 161 (20.0) <0.001
Framingham 1998 recalibrated 453 (11.8) 201 (24.9) <0.001
Results are expressed as number of participants (column %). Statistical analysis by chi-square. High cardiovascular disease risk is defined as a 10-year risk ≥5 % for
SCORE and as a 10-year risk ≥20 % for Framingham
Table 4 Multivariable analysis of the association between earlobe crease and personal history of cardiovascular disease, CoLaus
study, Lausanne, 2009–2012
Adjusted for Age and gender Age, gender and BMI
History of OR (95 % CI) P-value OR (95 % CI) P-value
Any CVD 1.55 (1.21; 1.98) <0.001 1.47 (1.14; 1.89) <0.01
Coronary artery disease 1.85 (1.30; 2.63) <0.001 1.80 (1.26; 2.58) <0.001
Angina pectoris 1.28 (0.81; 2.03) 0.30 1.19 (0.74; 1.90) 0.47
Myocardial infarction 1.69 (1.08; 2.64) <0.05 1.59 (1.01; 2.51) <0.05
Stroke 1.34 (0.84; 2.15) 0.23 1.30 (0.79; 2.11) 0.30
CABG 1.70 (0.97; 3.00) 0.07 1.67 (0.93; 2.99) 0.09
High CVD risk
SCORE recalibrated 1.11 (0.88; 1.41) 0.37 1.10 (0.87; 1.39) 0.44
Framingham 1998 1.09 (0.85; 1.41) 0.50 0.99 (0.76; 1.28) 0.91
Framingham 1998 r. 1.15 (0.91; 1.47) 0.25 1.04 (0.81; 1.34) 0.75
Results are expressed as adjusted odds ratio (95 % confidence interval) for presence relative to the absence of ELC. Statistical analysis by logistic regression
BMI body mass index; OR odds ratio; CVD cardiovascular disease; CABG coronary artery bypass graft; high cardiovascular disease risk defined as a 10-year risk ≥5 %
for SCORE and as a 10-year risk ≥20 % for Framingham. r. recalibrated
Aligisakis et al. BMC Cardiovascular Disorders  (2016) 16:17 Page 6 of 9
ELC was positively associated with hypertension, and this
association remained significant even after adjusting for
age, gender and BMI. Such association had already been
pointed out by some reports [8–10] but by another [13].
Contrary to BMI, no linear association between number of
ELC and prevalence of hypertension was found.
On bivariate analysis, ELC was associated with diabetes
and several markers of insulin resistance such as lower
HDL cholesterol and higher glucose, insulin, HOMA-IR
and triglycerides levels. Still, all associations became non-
significant after adjusting for BMI, a finding partly in agree-
ment with other studies [7, 8, 13]. Similarly, the association
between ELC and MS was no longer significant after
adjusting for BMI, a finding contradicting another
study which found a high association between ELC
and MS [11]. Overall, our results suggest that the as-
sociation between ELC and most metabolic markers
might be mediated by obesity levels.
Association between ELC and history or risk of CVD
ELC was significantly associated with personal history of
CVD (particularly CAD) independently of age, gender
and BMI; adjusting for waist circumference instead of
BMI or further adjustment for the main CVRF (hyper-
tension, smoking, total cholesterol and diabetes) led to
similar findings. Interestingly, the fact of having bilateral
ELC did not lead to a stronger association than having
unilateral ELC. Conversely, no association was found
between ELC and CVD risk scores after adjusting for
age, gender and BMI; the most likely explanation is that
age and gender are part of CVD risk equations and that
participants with ELC were older, thus leading to an
increased CVD risk. Overall, our results suggest that
ELC might be related to personal history of CVD but
not to absolute CVD risk.
The main hypothesis to explain the association between
ELC and CVD is that both organs have an end-artery-type
of microcirculation without collaterals [2–7]. Thus, athero-
sclerotic microvascular changes leading to anoxia in ear-
lobes and to the occurrence of ELC could reflect changes
in heart microcirculation. In other words, presence of an
ELC would be a marker of defective heart microcirculation.
Our findings of an independent association with hyperten-
sion which also has a negative impact on the microcircula-
tion are consistent with this hypothesis.
Association between ELC and other markers
Previous studies have explored the association between
ELC and obesity or MS [2, 8, 11] but data on the associ-
ations between ELC and other adiposity markers such as
leptin, adiponectin and uric acid are lacking. Our results
show that most bivariate associations between ELC and
metabolic, adiposity, inflammatory or liver markers were
no longer significant in multivariable analysis.
Still, a significant positive association was found between
ELC and IL-1β, independently of age, gender and BMI or
waist. IL-1β is a pro-inflammatory cytokine and has been
suggested to be involved in the pathogenesis of atheroscler-
osis and vascular and myocardial injury [38–40]. However,
in the CoLaus study IL-1β levels were not associated with
obesity [41].
Study limitations
This study has several limitations. Due to its cross-
sectional setting, it was not possible to estimate whether
presence of ELC is an independent predictor of CVD. A
follow-up study of this cohort is currently under way and
will hopefully provide an answer to this issue. Finally, this
study is based on a Caucasian population and the results
might not be applied to other ethnic groups.
Conclusion
Earlobe crease is significantly and independently associated
with higher prevalence of hypertension and personal
history of CVD. The association between ELC and the
other metabolic markers appears to be mediated by obesity.
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